Mark Yates, ACR 2020 – Risk Mitigating Behaviour during the COVID-19 Pandemic

We caught up with Mark Yates (King’s College London, London, UK) to discuss risk mitigating behaviours during the COVID-19 pandemic in patients with immune-mediated inflammatory diseases who use biologics. The abstract ‘Risk Mitigating Behaviour in People with Rheumatic Diseases or Psoriasis During the COVID-19 Pandemic Differ by Immunosuppressant Treatment Type: A Patient survey Study’ (ABSTRACT NUMBER: L02) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.

Questions

1. What is known about the risks of adverse COVID-19 outcomes in people with immune-mediated inflammatory diseases (IMIDs) who use biologics? (0:29)
2. How might risk-mitigating behaviours confound these findings? (1:49)
3. Could you tell us a little about your study in people with rheumatic diseases or psoriasis? (2:31)
4. What were the findings of the study? (3:40)
5. How can these data be used to improve communications between clinicians and vulnerable patients? (4:32)

Disclosures: Dr Yates reports receiving honoraria from Abbvie.

Support: Interview and filming supported by Touch Medical Media.

Filmed in coverage of the ACR Convergence 2020 (Virtual).